Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Garches – page 241

3 430 clinical trials in Garches, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Garches at a glance
3 430
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 430 trials in Garches

Open in trial search

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Neoplasm malignant+1

Not recruiting

Screening for Hidden Cancer Using FDG PET/CT and Gallium (68Ga) Chloride in Patients Aged 50+ with Unexplained Blood Clots

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA) chloride
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lorlatinib
  • Sponsor:Pfizer Inc.

Rhabdomyosarcoma+4

Not recruiting

Study of Lenvatinib for Children and Young Adults with Relapsed or Refractory Solid Tumors, Including High Grade Glioma and Rhabdomyosarcoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Systemic candida

Not recruiting

Study Comparing Ibrexafungerp and Fluconazole for Treating Candidemia or Invasive Candidiasis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anidulafungin
  • Sponsor:Scynexis Inc.

Malignant melanoma+1

Not recruiting

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Not recruiting

Study on the Safety and Anti-tumor Effects of GEN1042 Alone or with Pembrolizumab and Chemotherapy in Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Garches

What the registry says about research in the country

01 Neurological Disorders

Clinical trials focusing on innovative treatments for neuromuscular conditions and movement disorders, including studies on Spinal Muscular Atrophy and Myasthenia Gravis. Research examines novel drug delivery systems and therapeutic approaches for improving patient outcomes.

  • Spinal Muscular Atrophy Treatment
  • Myasthenia Gravis Management
  • Myotonic Dystrophy Research
02 Critical Care Medicine

Groundbreaking research in intensive care focusing on treating severe conditions like septic shock and immunosuppression. Studies evaluate new therapeutic approaches for improving survival rates and patient outcomes in critical care settings.

  • Sepsis Treatment Innovations
  • Immune System Support
  • Critical Care Interventions
03 Rare Diseases

Innovative clinical trials targeting rare genetic conditions including Pompe Disease and Fabry Disease. Research focuses on enzyme replacement therapies and novel treatment approaches to improve patient quality of life.

  • Enzyme Replacement Therapy
  • Genetic Disease Management
  • Pediatric Rare Disease Treatment
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.